These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18720145)

  • 1. Acido-basic properties of proton pump inhibitors in aqueous solutions.
    Kristl A
    Drug Dev Ind Pharm; 2009 Jan; 35(1):114-7. PubMed ID: 18720145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preformulation investigation of the novel proton pump inhibitor lansoprazole.
    Kristl A; Vrecer F
    Drug Dev Ind Pharm; 2000 Jul; 26(7):781-3. PubMed ID: 10872099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro investigation on acid catalyzed reactions of proton pump inhibitors in the absence of an electrophile.
    Tutunji MF; Qaisi AM; El-Eswed B; Tutunji LF
    Int J Pharm; 2006 Oct; 323(1-2):110-6. PubMed ID: 16860502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypersensitivity to lansoprazole with tolerance to other proton pump inhibitors: does cross-reactivity between proton pump inhibitors really exist?
    Karabacak E; Kutlu A; Aydin E; Ozturk S
    Allergol Immunopathol (Madr); 2013; 41(2):136-7. PubMed ID: 23137870
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
    Sharma VK
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole.
    Melkoumov A; Soukrati A; Elkin I; Forest JM; Hildgen P; Leclair G
    Am J Health Syst Pharm; 2011 Nov; 68(21):2069-74. PubMed ID: 22011986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
    Shin JM; Cho YM; Sachs G
    J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers.
    Kees F; Holstege A; Ittner KP; Zimmermann M; Lock G; Schölmerich J; Grobecker H
    Aliment Pharmacol Ther; 2000 Apr; 14(4):407-12. PubMed ID: 10759619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-dimensional chromatography method applied to the enantiomeric determination of lansoprazole in human plasma by direct sample injection.
    Gomes RF; Cassiano NM; Pedrazzoli J; Cass QB
    Chirality; 2010 Jan; 22(1):35-41. PubMed ID: 19229958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
    Meyer UA
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor.
    Baldi F; Malfertheiner P
    Digestion; 2003; 67(1-2):1-5. PubMed ID: 12743433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
    Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M; Burnham WR; Kamm MA
    Eur J Gastroenterol Hepatol; 1998 Sep; 10(9):753-8. PubMed ID: 9831269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.